{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:16:05Z","timestamp":1792430165809,"version":"4.5.0"},"reference-count":51,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,5,9]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>The combination of elotuzumab and an anti\u2013PD-1 antibody leads to enhanced antitumor efficacy in mouse models. Enhanced antitumor activity is likely due to the promotion of tumor-infiltrating NK and T-cell activity.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017004382","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T00:40:30Z","timestamp":1494290430000},"page":"753-765","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["PD-1 blockade enhances elotuzumab efficacy in mouse tumor models"],"prefix":"10.1182","volume":"1","author":[{"given":"Natalie A.","family":"Bezman","sequence":"first","affiliation":[{"name":"Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Jhatakia","sequence":"additional","affiliation":[{"name":"Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper Y.","family":"Kearney","sequence":"additional","affiliation":[{"name":"Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ty","family":"Brender","sequence":"additional","affiliation":[{"name":"Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Maurer","sequence":"additional","affiliation":[{"name":"Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Henning","sequence":"additional","affiliation":[{"name":"Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misty R.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Rogers","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Neeson","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Melbourne, VIC, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Korman","sequence":"additional","affiliation":[{"name":"Biologics Discovery California, Bristol-Myers Squibb, Redwood City, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Robbins","sequence":"additional","affiliation":[{"name":"Medical Oncology, Bristol-Myers Squibb, Princeton, NJ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Graziano","sequence":"additional","affiliation":[{"name":"Discovery Research, Bristol-Myers Squibb, Lawrenceville, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,5,8]]},"reference":[{"issue":"9668","key":"2019111616085291800_B1","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(09)60251-8","article-title":"Monoclonal antibodies for cancer immunotherapy","volume":"373","author":"Weiner","year":"2009","journal-title":"Lancet"},{"issue":"28","key":"2019111616085291800_B2","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1200\/JCO.2009.27.6360","article-title":"Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape","volume":"28","author":"Ferris","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111616085291800_B3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"issue":"4","key":"2019111616085291800_B4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.coi.2008.05.011","article-title":"Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies","volume":"20","author":"Taylor","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"12","key":"2019111616085291800_B5","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20040119","article-title":"The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy","volume":"199","author":"Uchida","year":"2004","journal-title":"J Exp Med"},{"issue":"18","key":"2019111616085291800_B6","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2013-04-497446","article-title":"Neutrophils mediate antibody-induced antitumor effects in mice","volume":"122","author":"Albanesi","year":"2013","journal-title":"Blood"},{"issue":"1-2","key":"2019111616085291800_B7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jim.2005.06.018","article-title":"CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells","volume":"304","author":"Bowles","year":"2005","journal-title":"J Immunol Methods"},{"issue":"21","key":"2019111616085291800_B8","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111616085291800_B9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"23","key":"2019111616085291800_B10","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2019111616085291800_B11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<30::AID-IMMU30>3.0.CO;2-D","article-title":"Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor","volume":"29","author":"Dyall","year":"1999","journal-title":"Eur J Immunol"},{"issue":"17","key":"2019111616085291800_B12","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Stagg","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111616085291800_B13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ccr.2010.06.014","article-title":"The therapeutic effect of anti-HER2\/neu antibody depends on both innate and adaptive immunity","volume":"18","author":"Park","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"2019111616085291800_B14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1182\/blood-2009-10-248609","article-title":"Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response","volume":"116","author":"Ab\u00e8s","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111616085291800_B15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/eji.1830270206","article-title":"Synergy between an antibody and CD8+ cells in eliminating an established tumor","volume":"27","author":"Vasovi\u0107","year":"1997","journal-title":"Eur J Immunol"},{"issue":"9","key":"2019111616085291800_B16","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111616085291800_B17","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111616085291800_B18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","article-title":"CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma","volume":"88","author":"Veillette","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"2019111616085291800_B19","unstructured":"Bristol-Myers Squibb. Empliciti (elotuzumab) prescribing information. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_empliciti.pdf. Accessed 5 May 2016."},{"issue":"7","key":"2019111616085291800_B20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"2019111616085291800_B21","unstructured":"European Medicines Agency. Elotuzumab: summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003967\/WC500206673.pdf. Accessed 20 June 2016."},{"key":"2019111616085291800_B22","unstructured":"National Institute of Pharmaceutical Medical Devices. New drugs approved in May 2016. Available at: http:\/\/www.pmda.go.jp\/files\/000216006.pdf. Accessed 8 March 2017."},{"issue":"9","key":"2019111616085291800_B23","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"van Rhee","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"2019111616085291800_B24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4711.4711","article-title":"Lirilumab enhances anti-tumor efficacy of elotuzumab [abstract]","volume":"124","author":"Sola","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111616085291800_B25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4717.4717","article-title":"Effects of IL-21, KIR blockade, and CD137 agonism on the non-clinical activity of elotuzumab [abstract]","volume":"124","author":"Robbins","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2019111616085291800_B26","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"2019111616085291800_B27","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.4049\/jimmunol.167.10.5517","article-title":"Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family","volume":"167","author":"Bouchon","year":"2001","journal-title":"J Immunol"},{"issue":"3","key":"2019111616085291800_B28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat Immunol"},{"issue":"1-2","key":"2019111616085291800_B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-5890(02)00094-9","article-title":"CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function","volume":"39","author":"Kumaresan","year":"2002","journal-title":"Mol Immunol"},{"issue":"1","key":"2019111616085291800_B30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1128\/MCB.01107-14","article-title":"Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells","volume":"35","author":"Guo","year":"2015","journal-title":"Mol Cell Biol"},{"issue":"5","key":"2019111616085291800_B31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2217\/imt.12.38","article-title":"Combination strategies to enhance antitumor ADCC","volume":"4","author":"Kohrt","year":"2012","journal-title":"Immunotherapy"},{"issue":"5","key":"2019111616085291800_B32","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cam4.106","article-title":"PD-1 as a potential target in cancer therapy","volume":"2","author":"McDermott","year":"2013","journal-title":"Cancer Med"},{"issue":"2","key":"2019111616085291800_B33","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","article-title":"SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation","volume":"173","author":"Chemnitz","year":"2004","journal-title":"J Immunol"},{"issue":"8","key":"2019111616085291800_B34","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"issue":"13","key":"2019111616085291800_B35","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"issue":"20","key":"2019111616085291800_B36","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2019111616085291800_B37","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2019111616085291800_B38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"2019111616085291800_B39","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111616085291800_B40","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1016\/S2352-3026(15)00197-0","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study","volume":"2","author":"Richardson","year":"2015","journal-title":"Lancet Haematol"},{"issue":"5","key":"2019111616085291800_B41","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-08-1825","article-title":"Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors","volume":"15","author":"Li","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111616085291800_B42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis [published correction appears in Cancer Cell. 2015;28(4):543]","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111616085291800_B43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-\u03b1 pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2019111616085291800_B44","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1189\/jlb.0310172","article-title":"Modulation of human neutrophil survival and antigen expression by activated CD4+ and CD8+ T cells","volume":"88","author":"Pelletier","year":"2010","journal-title":"J Leukoc Biol"},{"issue":"2","key":"2019111616085291800_B45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1189\/jlb.71.2.173","article-title":"Role of chemokines in the biology of natural killer cells","volume":"71","author":"Robertson","year":"2002","journal-title":"J Leukoc Biol"},{"issue":"5","key":"2019111616085291800_B46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cell.2015.04.016","article-title":"Differential Fc-receptor engagement drives an anti-tumor vaccinal effect","volume":"161","author":"DiLillo","year":"2015","journal-title":"Cell"},{"issue":"2","key":"2019111616085291800_B47","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nri.2015.9","article-title":"Natural killer cell memory in infection, inflammation and cancer","volume":"16","author":"Cerwenka","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2019111616085291800_B48","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"2019111616085291800_B49","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2019111616085291800_B50","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2010-08-301945","article-title":"CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies","volume":"117","author":"Kohrt","year":"2011","journal-title":"Blood"},{"issue":"7528","key":"2019111616085291800_B51","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/12\/753\/877200\/advances004382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/12\/753\/877200\/advances004382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T13:23:00Z","timestamp":1692796980000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/12\/753\/16010\/PD1-blockade-enhances-elotuzumab-efficacy-in-mouse"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,8]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,5,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017004382","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,8]]}}}